BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 08, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Gemzar gemcitabine: Phase III data

In an open-label, international Phase III trial in 515 patients with locally advanced cervical cancer, Gemzar plus standard of care (cisplatin and external radiation) met the primary endpoint of a significant increase in PFS at 3 years...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >